COPAXONE is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis. Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced, in conjunction with the release of the Sanofi-Aventis group’s financial results, that global in-market sales of Copaxone in the third quarter of 2006 grew by 15% as compared to the third quarter of 2005 and reached a record of $354 million.
According to IMS, in the U.S. Copaxone continues to outpace the market growth strengthening its leadership position with TRx and NRx shares increasing to 34% and 35.2%, respectively, as of September 2006. U.S. sales in the third quarter of 2006 increased 10% over the third quarter of 2005 to $226 million.
Outside the U.S., mainly in Europe, Copaxone is the fastest growing multiple sclerosis therapy with growth of 26% over the third quarter of 2005, reaching sales of $128M.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva’s sales are in North America and Europe.